Podcasts about Mash

ATTENTION! This is an audio recording of the latest MASH Matters video livestream. We strongly encourage you to WATCH this episode on YouTube to see Jeff & Ryan's ugly mugs (faces), pretty mugs (cups), old TV clips, and a surprise appearance by Walter Eugene Patrick! This livestream aired live on August 31, 2025. CLICK HERE TO WATCH THE LIVESTREAM REPLAY ON YOUTUBE

What kinds of things do neutron stars do? They can smash into each other, producing bright flashes of radiation and strong ripples in spacetime that can be detected across the universe! Or, a neutron star can just be sitting there, and its magnetic field might suddenly shift and produce a dramatic burst of radio waves! But mainly, neutron stars are super-dense and super-complicated, giving us a probe of fundamental physics in its most extreme limits. Dr. Wen-Fai Fong tells us all about how we can learn more!

Join us as we recap this classic 1970's sitcom. There's tons of fun trivia, discussion of the biggest pop culture news that dropped on the day we recorded this podcast and a discussion of Cheers without Sam and MASH with Hawkeye. We also mention: The Love Boat, Fantasy Island, Lucille Ball, Frasier and...Seinfeld!

THE BEST HUNGER GAMES MOVIE?! The Hunger Games: Catching Fire Full Movie Reaction Watch Along:   / thereelrejects   Get your New Customer offer + 3-month Unlimited wireless plan for just 15 bucks a month at https://www.mintmobile.com/REJECTS Support The Channel By Getting Some REEL REJECTS Aparrel! https://www.rejectnationshop.com/ With The Hunger Games: Sunrise on the Reaping on the horizon, Aaron & Andrew continue their journey giving their The Hunger Games: Catching Fire Reaction, Recap, Analysis, & Spoiler Review! The Hunger Games: Catching Fire (2013), directed by Francis Lawrence, continues the epic dystopian saga based on Suzanne Collins' bestselling novels. Jennifer Lawrence (Silver Linings Playbook, X-Men: First Class) returns as Katniss Everdeen, who finds herself once again thrust into the deadly Hunger Games arena after her defiance in the previous installment inspires rebellion across Panem. Josh Hutcherson (Bridge to Terabithia, The Kids Are All Right) stars as Peeta Mellark, her fellow victor and partner in survival, while Liam Hemsworth (The Last Song, Independence Day: Resurgence) plays Gale Hawthorne, torn between loyalty and revolution. Donald Sutherland (The Italian Job, MAS*H) returns as the chilling President Snow, joined by Philip Seymour Hoffman (Capote, The Master) as the sly new Gamemaker, Plutarch Heavensbee. Supporting performances include Woody Harrelson (True Detective, Zombieland) as Haymitch, Elizabeth Banks (Pitch Perfect, The Lego Movie) as Effie Trinket, and Stanley Tucci (The Devil Wears Prada, Spotlight) as the flamboyant Caesar Flickerman. From Katniss and Peeta's unforgettable Victory Tour to the shocking Quarter Quell reveal, the film builds to one of the franchise's most iconic cliffhangers. With stunning visuals, political intrigue, and the unforgettable “girl on fire” moments, Catching Fire set the stage for the Mockingjay films while cementing Katniss Everdeen as one of cinema's most enduring heroes. Join Aaron Alexander & Andrew Gordon as they react, review, and break down the most emotional, action-packed, and game-changing moments of this blockbuster sequel. Follow Aaron On Instagram: https://www.instagram.com/therealaaronalexander/?hl=en Follow Andrew Gordon on Socials:  YouTube: https://www.youtube.com/@MovieSource Instagram:  https://www.instagram.com/agor711/?hl=en Twitter:  https://twitter.com/Agor711 Intense Suspense by Audionautix is licensed under a Creative Commons Attribution 4.0 license. https://creativecommons.org/licenses/... Support The Channel By Getting Some REEL REJECTS Apparel! https://www.rejectnationshop.com/ Follow Us On Socials:  Instagram: https://www.instagram.com/reelrejects/  Tik-Tok: https://www.tiktok.com/@reelrejects?lang=en Twitter: https://x.com/reelrejects Facebook: https://www.facebook.com/TheReelRejects/ Music Used In Ad:  Hat the Jazz by Twin Musicom is licensed under a Creative Commons Attribution 4.0 license. https://creativecommons.org/licenses/by/4.0/ Happy Alley by Kevin MacLeod is licensed under a Creative Commons Attribution 4.0 license. https://creativecommons.org/licenses/... POWERED BY @GFUEL Visit https://gfuel.ly/3wD5Ygo and use code REJECTNATION for 20% off select tubs!! Head Editor: https://www.instagram.com/praperhq/?hl=en Co-Editor: Greg Alba Co-Editor: John Humphrey Music In Video: Airport Lounge - Disco Ultralounge by Kevin MacLeod is licensed under a Creative Commons Attribution 4.0 license. https://creativecommons.org/licenses/by/4.0/ Ask Us A QUESTION On CAMEO: https://www.cameo.com/thereelrejects Follow TheReelRejects On FACEBOOK, TWITTER, & INSTAGRAM:  FB:  https://www.facebook.com/TheReelRejects/ INSTAGRAM:  https://www.instagram.com/reelrejects/ TWITTER:  https://twitter.com/thereelrejects Follow GREG ON INSTAGRAM & TWITTER: INSTAGRAM:  https://www.instagram.com/thegregalba/ TWITTER:  https://twitter.com/thegregalba Learn more about your ad choices. Visit megaphone.fm/adchoices

Send us a textKey Opinion Leaders Manal Abdelmalek, Naim Alkhouri, Scott Isaacs and Zobair Younossi join Roger Green to discuss the FDA's approval of semaglutide for patients with non-cirrhotic MASH. This conversation focuses on how the US healthcare system must adapt to handle the growing number of MASH and MASLD patients who might seek treatment, given likely increases in publicity and education.The conversation starts with a focus on the implications of semaglutide approval for hepatologists. Naim states that many hepatologists are currently uncomfortable managing patients on GLP-1 agonists. This will need to change. Manal points out that providers must check for cirrhosis when testing for MASH and understand how to respond accordingly. An increase in the number of providers having access to in-office scanning devices will facilitate this process.Zobair shifts to a larger point:  even if all related specialists integrate MASH into their practices, the actual patient care demand will require alternative pathways in which the responsibility for patient care will rest with specialist APPs. The number of APPs necessary to handle this load and trained to do so does not currently exist in the US. Increased APP training must, and will, become an area for increased investment and focus.After Naim Alkhouri describes some of the differences between resmetirom and semaglutide in terms of practical treatment decisions, the discussion focuses on why MASLD and MASH will create unique challenges for hepatology practices. Manal views the issue as a matter of time; practices cannot absorb large numbers of new, non-urgent patients. Naim suggests that the real issue is the business question: specialists today do not profit simply from treating patients. Zobair agrees with Naim and notes that the challenge is not unique to hepatology. He expresses the hope that AI and efficient database management will make it easier to target, screen, diagnose and treat patients...given sufficient providers (mostly APPs) to treat them. 

Send us a textKey Opinion Leaders Manal Abdelmalek, Naim Alkhouri, Scott Isaacs and Zobair Younossi join Roger Green to discuss  FDA's approval of semaglutide for patients with non-cirrhotic MASH. This conversation focuses on benefits for patients and ways that having two drugs with different modes of action will change pharmacotherapy choices.This conversation starts with the group describing the sense of "enthusiasm" and "fulfillment" hepatology drug developers feel to see two drugs approved in the US and many other major changes to come (more drug approvals, FDA acceptance of a path to approval that is not based on liver biopsy). One interesting takeaway is that while the approval of semaglutide will likely change the number of patients treated with MASH pharmacotherapy, the greater impact of this approval will be on public awareness of MASH and the accompanying demand for treatment. In terms of actual drug use, the first major change will come among patients living with obesity but not Type 2 diabetes. Most of these patients previously saw their semaglutide prescriptions rejected for payment by health insurers. However, many of these patients will be living with MASH, and they are likely to see their prescriptions approved. Instead, the largest impact may involve increased education and awareness. Scott pointed out that endocrinologists, who frequently prescribe incretin agonists, will have reason to learn how to diagnose and manage MASH in patients they already treat. Zobair noted that an array of companies, starting with pharmaceutical manufacturers and scanning companies, will dramatically increase investments in prescriber and patient education. Another important benefit may come in terms of coverage. Scott points out that most patients living with obesity but not diabetes are unlikely to have their semaglutide prescriptions covered by commercial insurers. Those living with non-cirrhotic MASH are likely to have semaglutide covered. A separate but related point: Naim reports that ~30% of the MASH patients he sees are taking an incretin agonist at the time of initial visit.

Tommy Ruben joined me to discuss the closed knit cast of CPO Sharkey; growing up in Larchont, NY and his dad working for Sgt. Bilko; his dad Aaron, writing for Fred Allen, Milton Berle, Sid Caesar, The Andy Griffith Show and creating Gomer Pyle USMC; Don Rickles getting booed on Comic Relief; Sharkey's scripts scripts had ad-libs written in; being a class clown; guest starring on MASH; going to the Oakwood School; his dad''s film, The Comic; his father liked to build sitcoms around someone; creating CPO Sharkey; Polish jokes got the most letters; his first scene; episodes focusing on his character; the Johnny Carson incident and how has dad was mad; NBC wasn't all in on Don; Bob Newhart; his brother writing the punk rock episode; appearing in More American Graffiti with Cindy Williams; the difference in Drew Barrymore and James garner's acting methods; appearing and writing and episodes of The Stockard Channing Show; Rhonda Bates; being in his brothers movies; almost getting The Hardy Boys Show; and studying photography at the School of Visual Arts.

Send us a text00:00:00 - Surf's Up, Season 6, Episode 12This week's episode is a special three-part roundtable on the implications of the FDA's recent approval of semaglutide. Naim Alkhouri, Manal Abdelmalek, Scott Isaacs and Zobair Younossi join Roger Green in a discussion that focuses less on specifics of pharmacotherapy and more on how having two drugs available will change MASH management in the US.00:08:45 - Part I: How Will The Semaglutide Approval Affect Patient Treatment and Pharmacotherapy?The group starts by describing the sense of "enthusiasm" and "fulfillment" hepatology drug developers feel to see two drugs approved in the US and many other major changes to come (more drug approvals, FDA acceptance of a path to approval that is not based on liver biopsy). One interesting takeaway is that while the approval of semaglutide will likely change the number of patients treated with MASH pharmacotherapy, the greater impact of this approval will be on public awareness of MASH and the accompanying demand for treatment. In terms of actual drug use, the first major change will come among patients living with obesity but not Type 2 diabetes. Most of these patients previously saw their semaglutide prescriptions rejected for payment by health insurers. However, many of these patients will be living with MASH, and they are likely to see their prescriptions approved. Instead, the largest impact may involve increased education and awareness. Scott pointed out that endocrinologists, who frequently prescribe incretin agonists, will have reason to learn how to diagnose and manage MASH in patients they already treat. Zobair noted that an array of companies, starting with pharmaceutical manufacturers and scanning companies, will dramatically increase investments in prescriber and patient education.00:25:30 - Part II: How the Structure of Medical Practice Is Likely To ChangeNaim states that many hepatologists are currently uncomfortable managing patients on GLP-1 agonists. This will need to change. Manal points out that providers must check for cirrhosis when testing for MASH and understand how to respond accordingly. An increase in the number of providers having access to in-office scanning devices will facilitate this process. Zobair states that even if all related specialists integrate MASH into their practices, the actual patient care demand will require alternative pathways in which the responsibility for patient care will rest with specialist APPs. After Naim Alkhouri describes some of the differences between resmetirom and semaglutide in terms of practical treatment decisions, the discussion focuses on why MASLD and MASH will create unique challenges for hepatology practices. Manal views the issue as a matter of time; practices cannot absorb large numbers of new, non-urgent patients. Naim suggests that the real issue is the business question: specialists today do not profit simply from treating patients. Zobair agrees with Naim and notes that the challenge is not unique to hepatology. He expresses the hope that AI and efficient database management will make it easier to target patients, screen, diagnose and treat them. 00:44:17 - Part III: What Happens Next?In this final section, panelists identify some of the changes they foresee if we are to manage the tsunami of undiagnosed MASLD patients. Many of the comments touch on themes discussed earlier in this episode, but a couple are unique. Zobair states we must remember that the vast majority of MASLD patients will never develop MASH. Manal foresees a more sophisticated approach to selecting pharmacotherapies as prescribers have a broader set of options, each with its own benefits and drawbacks. Scotts anticipates a "paradigm shift" in which providers come to view MASH similarly to how they view diabetic comorbidities. 

The FDA has granted accelerated approval to semaglutide (Wegovy) as the first drug for metabolic dysfunction–associated steatohepatitis (MASH), showing significant improvements in liver health and weight loss in the phase 3 ESSENCE trial. A systematic review of acetaminophen use in pregnancy found potential risks with long-term or frequent use but confirmed short-term, low-dose use remains appropriate when needed. Finally, an AI model integrating MRI, biomarkers, and clinical data improved prediction of knee osteoarthritis progression, enhancing physician accuracy and suggesting future support for earlier, personalized interventions.

It's the first week of school, and who better to help us kick off Season 3 than Lorraine (@all_things_primary)? As ever, Lorraine gives practical, sensible advice on how we can build relationships with our new students, starting on the first day (or even beforehand) and continuing throughout the year. Hugh veers wildly between excitement and terror at the prospect of his first Junior Infants class, while Jane is full of plans for another great year in 6th Class.Follow us @thatllteachyoupodcast on Instagram and Tiktok.Please rate, review recommend!This episode of That'll Teach You is sponsored by Mash.ie, the number one platform for Irish teachers to buy and sell resources online. Hosted on Acast. See acast.com/privacy for more information.

"If you love cats, you should be concerned about trying to help bring those numbers down so animals don't suffer because this is why we do this. We don't want animals suffering, having unwanted litters of cats and having to have them suffer." This episode is sponsored-in-part by Maddie's Fund and 6 Degrees of Cats. In this powerful episode, host Stacy LeBaron sits down with Cathy Bissell, founder of Bissell Pet Foundation, who has revolutionized animal welfare through innovative programs reaching over 6,000 shelters across 49 states. From her unexpected entry into animal welfare during Hurricane Katrina to creating the nation's largest funded adoption event, Cathy's journey demonstrates how strategic thinking and passionate commitment can create systemic change. Her foundation has impacted nearly one million pets since 2011, but it's her latest initiative that's truly disrupting the industry. Cathy shares the incredible success of her groundbreaking "Fix the Future" program, launched in 2023 to address the veterinary care access crisis. In just under 18 months, this free spay/neuter initiative has sterilized 138,000 animals across 27 states, with an astounding 86,963 of those being cats. Through a network of 385 high-volume, high-quality relief veterinarians, the program is tackling overpopulation at its source while keeping costs remarkably low at just $35 per surgery. Cathy discusses the challenges of scaling this model, the importance of treating every animal that comes through their doors, and why she believes this "disruptor program" is essential for breaking down cost barriers that prevent people from accessing veterinary care. Whether you're working in a small grassroots rescue or leading a major shelter, this episode provides invaluable insights into creating sustainable, scalable solutions that address root causes rather than just symptoms. Cathy's emphasis on collaboration, her honest discussion about learning from mistakes (including a powerful story about declawing), and her practical advice for getting started at any age will inspire listeners to think bigger about their impact and consider how they can contribute to solving the access to care crisis in their own communities. Press play now for: Cathy's unexpected journey from Hurricane Katrina volunteer to founding a major animal welfare foundation The evolution from disaster response to adoption events to addressing systemic access to care challenges Incredible statistics: 138,000 spay/neuter surgeries in 18 months with 86,963 cats across 27 states How the Fix the Future program operates with 385 relief veterinarians at just $35 per surgery The power of MASH-style clinics and why community cat advocates should consider creating their own Why Michigan serves as a prime example with 3,000 cats out of 4,000 total surgeries at their clinic The importance of spaying/neutering before adoption and addressing kittens under six months How veterinary school limitations (graduating with only 1-3 spay/neuter surgeries) impact private practice capacity Cathy's honest story about learning from the declawing controversy and how it changed her foundation's policies Practical advice for getting involved at any age and making a difference beyond just donating money The role of Empty the Shelters adoption events in supporting shelter operations nationwide Why every animal deserves vaccination and ear-tipping as part of comprehensive TNR programs Resources mentioned: Bissell Pet Foundation website (https://www.bissellpetfoundation.org/) Empty the Shelters adoption events (https://www.bissellpetfoundation.org/programs/empty-the-shelters/) Fix the Future spay/neuter initiative (https://www.bissellpetfoundation.org/programs/fix-the-future/) Mississippi State University College of Veterinary Medicine (https://www.vetmed.msstate.edu/) MSU shelter medicine program details (https://www.vetmed.msstate.edu/about/points-of-pride) United Spay Alliance website (https://www.unitedspayalliance.org/) United Spay Alliance wet lab training programs (https://www.unitedspayalliance.org/hqhvsn-wet-labs/) BISSELL Pet Foundation grant information (https://www.bissellpetfoundation.org/grant-information/) Operation Fix the Future clinics (https://www.bissellpetfoundation.org/operation-fix-the-future/) BISSELL Pet Foundation Facebook page (https://www.facebook.com/bissellpets/) Sponsor Links: Maddie's Fund (https://www.communitycatspodcast.com/maddies623) Six Degrees of Cats (https://podcasts.apple.com/us/podcast/6-degrees-of-cats/id1669849217) Follow & Review We'd love for you to follow us if you haven't yet. Click that purple '+' in the top right corner of your Apple Podcasts app. We'd love it even more if you could drop a review or 5-star rating over on Apple Podcasts(https://podcasts.apple.com/us/podcast/the-community-cats-podcast/id1125752101?mt=2). Select “Ratings and Reviews” and “Write a Review” then share a quick line with your favorite part of the episode. It only takes a second and it helps spread the word about the podcast.

Send us a message with this link, we would love to hear from you. Standard message rates may apply.The liver performs vital functions including filtering toxins, producing proteins, storing energy, aiding digestion, and regulating cholesterol and hormones. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) has become the most common chronic liver disease globally, affecting up to 38% of the population worldwide.• The liver filters blood, breaks down alcohol and medications, produces proteins like albumin and clotting factors• It stores energy as glycogen, vitamins, and minerals including iron• The liver makes bile for digesting fats and helps regulate cholesterol and support immune function• Common liver problems include fatty liver disease, alcohol use, viral infections, and medication toxicity• MASLD (formerly non-alcoholic fatty liver disease) occurs when too much fat builds up in the liver• MASH is a severe form of MASLD with inflammation and damage that can lead to fibrosis and cirrhosis• Up to 38% of people worldwide have MASLD, with prevalence rising to 65% in those with type 2 diabetes• 5-10% total body weight loss can help slow, stop or reverse liver injury from MASLD• The FDA recently approved semaglutide (Wegovy) as the first specific medication for treating MASH• Regular check-ups with blood tests can help detect liver problems before symptoms developStay healthy, and if you're concerned about your liver health, speak with your healthcare provider about testing and treatment options.Support the showSubscribe to Our Newsletter! Production and Content: Edward Delesky, MD & Nicole Aruffo, RNArtwork: Olivia Pawlowski

Did you know that nearly one in three people with obesity may have fatty liver disease without even knowing it? In this episode, I talk about groundbreaking news in obesity and liver health, focusing on the FDA's recent approval of WeGovy to treat metabolic dysfunction associated steatohepatitis (MASH) with moderate to advanced fibrosis. I share a personal story about a friend who once struggled with fatigue, abnormal liver tests, and fatty liver disease, highlighting how limited treatment options used to be. I explain what MASH is, why it's so serious, and how common it is, especially among people with obesity and metabolic syndrome.  Furthermore, I dive into the ESSENCE trial, which showed that WeGovy not only improved liver inflammation and scarring but in some cases even reversed the disease, all while emphasizing that it works best when combined with lifestyle changes like healthy eating and regular activity.  Don't miss this episode where I break down the latest breakthrough in liver and weight loss care that could change your health journey!   Episode Highlights: FDA approval of WeGovy for treating MASH with fibrosis The ESSENCE trial results showing improvements in liver health Understanding what MASH is and why it's so common Importance of combining medication with lifestyle changes Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, “Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

Audio roundup of selected biopharma industry content from Scrip over the business week ended August 22, 2025. In this episode: Madrigal regains MASH lead with EU Rezdiffra approval; Viking's obesity data scare investors; China assets lead GLP-1 deals; CSL and others restructure; and Indegene exec on DTP and MFN policies. https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-T77LV22VANAL5GNPCC2YUVLZBE/ This episode was produced with the help of AI text-to-voice and voice emulation tools. Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

Jesus challenges our understanding of neighborliness through the parable of the Good Samaritan. While religious leaders passed by a wounded man, a Samaritan - someone from a despised group - showed extraordinary compassion. This story redefines 'neighbor' not by cultural, religious, or ethnic boundaries, but by showing mercy to those in need. As disciples of Christ, we must focus less on who qualifies as our neighbor and more on being the best neighbor to anyone God puts in our path. Like a MASH unit positioned near battlefields, we are called to care for all who come our way, regardless of background.

Öris ringer in från en dammig landsväg på Sicilien och berättar om upplevelsen att gå på Catanias seriepremiär efter att ha testat en häst mix grill på gatan, Stockholms skenande ölpriser, en hyfsat dramatisk Allsvensk omgång, Gyökeres målskytte och press inifrån och utifrån, Malmös bulla sponsevent och Alexander Isaks transfercirkus.I Eftersnacket: Trumps cankles, Vattenfalls okänsla, korruption och insider trading och den nya lagen om förolämpning av tjänsteman.

In this Q&A Mash episode, we answer your burning questions around weight loss resistance, hormone chaos, gut health confusion, and the BS behind one-size-fits-all advice. Liz and Becca dive deep into how context matters more than any single lab result, macro count, or training plan. Inside, we cover: What under-eating really does to your metabolism How overtraining wrecks your hormones Why “normal” labs don't mean jack The #1 mindset shift that moves the needle in healing This episode is your permission slip to stop doing “more” and start doing what's right for your body. *** Get Your Tickets Now: Use code REVIVAL for $100 discount ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠FitMom | UNSTUCK: The Women's Health & Hormone Summit⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ *** Gut & Hormones all messed up? ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠➡️ Take the quiz⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ***

22.08.25 Pt 2 Gareth Cliff and Ben Karpinski dive into a wild story about a woman who celebrated beating cancer by hooking up with 200 men — sparking a broader discussion about the secrets and strange origins of Scientology, from alien myths to modern controversies. Mash joins in with a look at the latest lifestyle buzz around “Ozempic butt,” as well as the dangers of self-driving cars that can unexpectedly grind to a halt in the middle of the road. To end things off on a high note, the team celebrates this week's Beautiful Moment: proudly South African words like “gatvol” officially making their way into the Oxford Dictionary. The Real Network

In this episode, our host Maryam Tabatabai is joined by three guests Olivia Pane, PharmD; Dr. Edmundo Rodriguez Frias; and Katie Lockhart, who unpack insights from Prime Therapeutics' latest clinical report that dives into the latest evidence-based clinical insights related to the rising prevalence and significant health impact of metabolic dysfunction-associated steatohepatitis, or MASH. MASH is a silent but serious liver condition affecting over 22 million Americans, with numbers projected to rise sharply by 2030. Listeners learn about the latest major development in liver health treatment: the FDA approval of Novo Nordisk's semaglutide – Wegovy -- as the first GLP-1 drug indicated for MASH. We explore how this development may revolutionize care and could offer a more affordable alternative to treating this condition.The Evolution of GLP-1swww.primetherapeutics.comAll Pharmacy Friends episodesMetabolic dysfunction-associated steatohepatitis (MASH) – A new era in liver healthThe views and opinions expressed by the guest featured on this podcast are their own and do not necessarily reflect the official policy or position of Prime Therapeutics LLC, its hosts, or its affiliates. The guest's appearance on this podcast does not imply an endorsement of their views, products, or services by Prime Therapeutics LLC. All content provided is for informational purposes only and should not be construed as professional advice

Great news! If you make a purchase from any link of the links below, the channel earns a small affiliate commission from the site. Many thanks ahead of time. BETTER HELP: https://www.betterhelp.com/JAYREELZ save 10% OFF of your first month. OLIPOP Soda: https://www.drinkolipop.com use promo code JAYREELZ for 15% off of your purchase. BOMBA SOCKS: https://www.gopjn.com/t/2-561785-354075-142593 SAVE 20% CONSUMER CELLULAR: https://www.pntrs.com/t/2-593611-354075-293459 Please subscribe, leave a rating and post a review on Apple Podcasts, Google Podcasts, Spotify, Audacy, Amazon Music and iHeartRadio or wherever you get your podcasts. For daily shorts, weekly vlogs and then some, please subscribe to my YouTube channel at: https://www.youtube.com/channel/UCMucZq-BQrUrpuQzQ-jYF7w If you'd like to contribute to the production of the podcast, please visit my Patreon page at: www.patreon.com/TheJAYREELZPodcast   Many thanks for all of your love and support.   Intro/outro music by Cyklonus. LINKS TO SUBSCRIBE, RATE & REVIEW: APPLE: https://podcasts.apple.com/us/podcast/the-jayreelz-podcast/id1354797894 SPOTIFY: https://open.spotify.com/show/7jtCQwuPOg334jmZ0xiA2D?si=22c9a582ef7a4566 AUDACY: https://www.audacy.com/podcast/the-jayreelz-podcast-d9f50 iHEARTRADIO: https://www.iheart.com/podcast/256-the-jayreelz-podcast-43104270/ AMAZON MUSIC: https://www.amazon.com/The-JAYREELZ-Podcast/dp/B08K58SW24/ref=sr_1_1?dchild=1&keywords=the+jayreelz+podcast&qid=1606319520&sr=8-1

The American Academy of Pediatrics release their own immunization schedule; The American Heart Association update 2017 guidelines for the prevention of high blood pressure; weight loss drug gains indication to treat noncirrhotic MASH; FDA approve a new fibromyalgia treatment; investigational SCD Tx to meet trial endpoint.

Three months after taking heat over an error-riddled first report, Health Secretary Robert F. Kennedy's Make America Healthy Again Commission was due to submit a new strategy report to President Donald Trump last week. While the report is delayed—for disputed reasons— Politico obtained a draft copy, which homes in on creating a new vaccine framework and streamlining access to investigational drugs, specifically for children. The new strategy also touches on pharma lobbying, with plans to address alleged conflicts of interest within HHS—which, incidentally, a new JAMA study found have dropped dramatically over the past 25 years. In other HHS news, Kennedy is reviving the Task Force on Safer Childhood Vaccines—which has been dormant for 30 years, and the secretary voiced his support of mRNA vaccines for cancer.   Meanwhile, weight loss continues to coral the headlines. Viking Therapeutics reported greater than 12% weight loss after 13 weeks for its obesity pill VK2735, but tolerability tanked the biotech's stock. As Viking, Eli Lilly and Novo Nordisk begin to report data from these oral options, manufacturing comes into focus, and Novo's pending approval of an oral form of Wegovy specifically puts the spotlight on the variability of high-dose peptides.  Speaking of Novo, the Danish pharma appears to be sucking in some oxygen after a difficult run. Last week, the FDA approved Wegovy as just the second drug for metabolic dysfunction-associated steatohepatitis (MASH), and on Monday, Novo teamed up with GoodRx to offer Wegovy and Ozempic and $499 per month if patients skip insurance. Not to be outdone, fellow weight loss warrior Lilly announced a $1.3 billion partnership with AI/ML startup Superluminal Medicines to advance new small molecules for cardiometabolic diseases and obesity. Lilly has also been active on the policy front, saying that it will soon announce higher prices for its drugs in markets like Europe in an effort to “align prices across developed countries.”  Always a contentious topic, pricing plays a key role in why the pharmaceutical industry fails to command the same respect as steelworkers or other all-American pursuits. Also in BioPharm Executive this week, BioSpace takes a deep dive into how the Trump administration is using Most Favored Nation pricing to target pharma companies and pursue a broader trade war.  

Hollywood actor Alan Alda has devoted his life to science, by taking his acting and communication skills off the screen and into the laboratory.Alan grew up in a show business family and spent his childhood touring with a burlesque show run by his parents.He eventually made a name for himself in showbiz, becoming well-known and much-loved for his performances in M.A.S.H. and The West Wing, as well as his roles in many Hollywood films.Alan is also famous for his love of science.He wrote Dear Albert for the stage, based on the love letters of Albert Einstein, which reveal Einstein as a beautifully passionate man.Alan has used his acting for the good of science by teaching communication skills to scientists so they might make their work better known and better understood.Further informationFirst broadcast December 2016.2025 update:  Alan has been diagnosed with Parkinson's disease, but he says he's managing it well.  Alan is still working occasionally, most recently in the TV remake of his 1981 film ‘The Four Seasons'.You can read all about the Conversations origin story on the ABC News website.This episode of Conversations explores science, science communication, MASH, television, Hollywood, silver screen, acting, show biz families, family business, Vietnam, origin stories, memoir.To binge even more great episodes of the Conversations podcast with Richard Fidler and Sarah Kanowski go the ABC listen app (Australia) or wherever you get your podcasts. There you'll find hundreds of the best thought-provoking interviews with authors, writers, artists, politicians, psychologists, musicians, and celebrities.

This Day in Legal History: Nineteenth Amendment RatifiedOn August 18, 1920, the Nineteenth Amendment to the U.S. Constitution was ratified, guaranteeing women the right to vote and marking a major legal milestone in the struggle for gender equality. The amendment states simply: “The right of citizens of the United States to vote shall not be denied or abridged… on account of sex.” Its passage capped off more than 70 years of organized activism, dating back to the Seneca Falls Convention in 1848. Suffragists like Susan B. Anthony, Elizabeth Cady Stanton, Sojourner Truth, and Alice Paul played pivotal roles in maintaining momentum across generations, despite fierce opposition.The road to ratification was grueling. Congress passed the amendment in 1919, but it still required approval from three-fourths of the states—36 at the time. Tennessee became the critical 36th state, narrowly approving the amendment in a dramatic vote where a 24-year-old legislator, Harry T. Burn, changed his vote after receiving a letter from his mother urging him to support suffrage. That moment tipped the scales and enshrined the right to vote for women nationwide.Before the amendment, several western states had already extended suffrage to women, but many others actively suppressed it. The legal recognition of women's voting rights through constitutional amendment removed any ambiguity and forced all states to comply. The Nineteenth Amendment not only transformed the electorate but also reshaped American democracy by recognizing women as full political participants.The Trump administration is accusing a federal judge in Boston of undermining the authority of the U.S. Supreme Court by continuing to block the administration from firing staff in the Department of Education's Office for Civil Rights. U.S. District Judge Myong Joun had issued an injunction requiring the reinstatement of employees let go in a mass layoff, despite the Supreme Court having recently paused a broader version of that order. The Justice Department has asked the 1st U.S. Circuit Court of Appeals to intervene, arguing that Joun's refusal to lift the narrower injunction contradicts the Supreme Court's ruling and undermines the rule of law.The judge's decision stems from a lawsuit challenging Secretary of Education Linda McMahon's plan to lay off over 1,300 department employees, part of President Trump's broader goal of eliminating the department—something only Congress can authorize. The plaintiffs, including students and advocacy groups, focused specifically on the Office for Civil Rights, which was set to lose half its staff. They argue that lifting the injunction now would effectively reward the administration's ongoing failure to comply with the court's order, as the terminated employees have not yet been reinstated.Judge Joun, appointed by President Biden, criticized the Supreme Court's ruling as "unreasoned" and pointed to the administration's continued noncompliance. The 1st Circuit has asked the plaintiffs to respond promptly to the Justice Department's request, signaling an expedited review.Trump administration claims judge defied Supreme Court to bar Education Department firings | ReutersFederal Reserve Chair Jerome Powell is preparing for what may be his final speech at the annual Jackson Hole conference, facing a complicated economic picture that challenges his data-driven policy approach. In past years, Powell used the conference to pledge aggressive action against inflation and, later, to support the labor market. Now, with inflation still above target and signs of economic slowdown emerging, Powell must decide whether to prioritize price stability or job preservation.The Trump administration and many investors expect interest rate cuts at the Fed's September meeting, but Powell's messaging—how he frames future actions—may matter more than the decision itself. Internally, Fed officials are split: some want to move quickly to protect jobs, while others want to wait for clearer evidence that inflation won't rebound. Powell has previously styled himself after past Fed chairs like Paul Volcker and Alan Greenspan, with Volcker's inflation-fighting resolve and Greenspan's forward-looking leniency both offering competing models.Recent economic data has sent mixed signals. Revised job growth numbers were lower than initially reported, supporting arguments for easing monetary policy, but inflation has edged up again. Trump's tariff policies add further uncertainty, though their economic impact has so far been less severe than feared. With the economy growing slowly and inflation still above the Fed's 2% target, Powell must decide whether to stay the course, cut rates cautiously, or begin a broader shift.Powell has used Jackson Hole to battle inflation and buoy jobs; he's now caught between both | ReutersNovo Nordisk's shares rose by up to 5% after receiving accelerated U.S. approval for its weight-loss drug Wegovy to treat MASH (metabolic dysfunction-associated steatohepatitis), a progressive liver disease that affects about 5% of U.S. adults. This marks the first GLP-1 drug approved for MASH and offers a significant, if temporary, advantage over competitor Eli Lilly, which is still in clinical trials for its own MASH-targeting drug, tirzepatide.The news was a welcome reversal for Novo, which recently lost over $70 billion in market value following a profit warning and leadership change. The company, once Europe's most valuable publicly traded firm due to Wegovy's success, has seen its share price drop sharply over the past year amid intensifying competition in the obesity drug market and the rise of compounded copycat drugs.Although Novo now holds a short-term lead in the liver disease market, analysts expect that exclusivity will be brief once Eli Lilly gains approval. Novo has also submitted applications in Europe and Japan, signaling its intention to secure broader global use for Wegovy beyond weight loss.Shares in Novo Nordisk rise after Wegovy gets US nod for liver disease treatment | ReutersNorton Rose's ambitious tech partnership with NMBL Technologies has ended in failure and mutual lawsuits, highlighting how difficult it is for Big Law firms to pivot from selling legal services to selling tech products. The firm's Chicago office, launched in 2022 as an “innovation hub,” aimed to introduce 150 clients to Proxy, a legal workflow tool developed by a new partner, Daniel Farris. But three years later, not a single sale was made. NMBL claims Norton Rose didn't uphold its end of the deal and stifled the rollout, while the firm says clients weren't interested and is seeking damages for the investment.The fallout underscores broader challenges law firms face as they increasingly invest in artificial intelligence and legal tech amid growing demand and rising budgets. Unlike traditional legal work, selling products requires different infrastructure and skills—such as dedicated sales teams—that most law firms lack. Despite producing marketing materials and training resources, NMBL alleges that very few Norton Rose lawyers engaged with the product and that the firm failed to meaningfully promote it.NMBL is seeking $15 million in damages, accusing the firm of using the deal merely to recruit talent, while Norton Rose wants $250,000, calling the product commercially nonviable. The firm also allegedly created a shell subsidiary, LX, to meet contract terms but never properly funded or activated it. This case illustrates the steep learning curve law firms face in transitioning to tech-based business models and the internal resistance that can derail innovation.Firm's Failed Tech Venture Foretells Big Law's AI Sales Struggle This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.minimumcomp.com/subscribe

What is a Zen teacher? What can a Zen teacher give you? This commentary was given on the day after her Zen teacher sanctioning ceremony. Teisho by Sensei Jissai Prince-Cherry.  Automated Transcript The post Blue Cliff Record #11: “Obaku's ‘Mash Eaters'” appeared first on Rochester Zen Center.

Liver, Lipids, and the Left Ventricle

Send us a textMulti-Metabolic Week focuses on the idea that MASLD and MASH are elements in a systemic set of Multi-Metabolic issues. This conversation is the second of two looking at the concept of the "Multi-Metabolic Clinic," a clinic that treats the entire spectrum of multi-metabolic diseases.This conversation starts by focusing on how the two clinics train other physicians and practices on multi-metabolic issues. The EDOM clinic in Spain is certified to provide nutritional training to other practices across the country, while the newer, smaller Trajectory Health Partners practice provides support on use of FibroScan and, more recently, Velacur from Sonic Incytes. Louise notes how important training is for optimal use of scanning devices, which includes both technical proficiency and knowledge of how to educate and motivate patients using the results of the scans. From there, the conversations shifts to focus on differences between treating patients in a conventional practice vs. a multi-metabolic one. The key differences involve length of patient visit and use of allied providers to educate patients more fully. Next, Louise asks whether the clinics have data on reducing the number of patients needing to go to a hospital. EDOM has data while the younger Trajectory has a clear sense this happens but no large-scale practice data to support this sense. Louise's last question is to ask how each physician would "sell" colleagues in their specialty on why to set up a multi-metabolic practice. The answers reflect the different specialties in which the physicians were trained originally (endocrinology in Spain, gastroenterology in the U.S.) but have significant common elements. 

Send us a textThis week's expert interview is with Dr. Emily Andaya, Medical Director of the Cardiovascular Program at Major Health Partners of Shelbyville, IN. She joins Louise Campbell and Roger Green to discuss the American Heart Assocation's CKM initiative, why she believe it should be titled "CKLM" for liver, and how including liver in the CKM scoring system would make it stronger and provide a more robust tool to help improve patients' health. Emily begins by discussing her attendance at the American Society for Preventive Cardiology meeting in Boston the previous weekend, where Dr. Christos Montzoros presented a talk proposing that the liver's role in cardiovascular diseases is "equally critical" compared to the kidney and other multi-metabolic co-morbidities. Dr. Montzoros closed his talk by stating that the CKM syndrome description should be changed to CKLM to reflect the importance of the liver, and that the CKLM patient scoring and criteria should reflect this as well.Next, Emily describes the 0-to-4 scoring system that the CKM initiative has chosen to use and the recommendations that accompany the scoring system itself. The system does not neatly overlay the 4-point fibrosis scoring system or the NAS score, but Emily describes how these might be incorporated into the CKM score. The conversation shifts to focus on patient management. Since the original CKM paper was published in 2023, resmetirom had not yet been approved and the paper itself focused more on screening than on treatment. To Emily, adding the "L" to CKM would entail adding resmetirom to treatment protocols as appropriate, and also considering drug combinations that addressed liver disease. Louise takes this issue from the other side, suggesting that every time a provider prescribes a drug to a CKM patient, the potential for negative liver effects should be part of the selection process. Emily and Louise agree that providers and patients should take a holistic approach to therapy for these patients. One benefit: even if a patient has multiple organs affected by multi-metabolic challenges, the provider can educate the patient that there is a single target disease to treat instead of multiple different diseases. As Roger notes, treating 4-5 discrete diseases simultaneously sounds overwhelming, while treating one overarching disease sounds far more manageable.The conversation ends with a focus on whether we are correctly identifying high-risk cardiovascular patients in the current environment, and how this more holistic focus might improve patient screening and identification.

After far too much time away, fair-weather co-host Ash Frith re-joins CheapShow just ahead of its 450th episode and what an episode! It's a nice chunky one that throws Ash in at the deep end straight from the start. They've all got a lot to catch up on and it's been a while since they've all been in the House of Sausage and Mash. It all leads to a 40 minute diversion into the sex, drugs and Rock & Roll private lives of comedians from yesteryear! It's getting censored to F***! After that, it's time for a classic Price of Shite and, to make things more challenging for our returning guest, Eli's confidence and ego is off the charts. There is a mix of tat, toys and musical surprises that must be priced rightly and Paul is struggling to juggle his loyalties! One more episode until 450, it's exciting! See pics/videos for this episode on our website: https://www.thecheapshow.co.uk/ep-449-mumchance SEE US LIVE: Oct 18th @ The Cheerful Earful Podcast Festival 2.30pm, London https://cheerfulearful.podlifeevents.com/festival/cheapshow---live-from-cheerful-earful-podcast-festival-18th-oct-2025-tickets Watch Our 10th Birthday YouTube Live Stream! https://youtube.com/live/Z18i8M3Eqac?feature=share And if you like us, why not support us: www.patreon.com/cheapshow If you want to get involved, email us at thecheapshow@gmail.com For all other information, please visit: www.thecheapshow.co.uk Like, Review, Share, Comment... LOVE US! MERCH Official CheapShow Magazine Shop: www.cheapmag.shop Send Us Stuff: CheapShow PO BOX 1309 Harrow HA1 9QJ

Send us a textMulti-Metabolic Week focuses on the idea that MASLD and MASH are elements in a systemic set of Multi-Metabolic issues. This conversation is the first of two looking at the concept of the "Multi-Metabolic Clinic," a clinic that treats the entire spectrum of multi-metabolic diseases. The core of this episode starts during the weekly groundbreaker exercise, during which our guests began to describe the path that brought them from single-disease specialization to the broader multi-metabolic practice.. Immediately after the groundbreakers, participants describe their clinics today, including patient population and principles underlying their approach to treatment. For Karen, the path started in a conventional gastrointestinal practice. A decade ago, she gained certification in obesity medicine. While treating patients for obesity, she came to appreciate the interplay of obesity, diabetes and the other manifestations of multi-metabolic disease. Eventually, she divided her practice and time so that she spent half her time in the GI practice and the other half creating Trajectory Health Partners, a practice focused on overall metabolic health.For Dr. López, the initial goal was to "re-educate the hypothalamic problem," which he saw as the root cause of obesity and from which all other metabolic issues came. He describes this as "the auto-destruction button" of patients' lives, leading to two causes of death: (1) insulin resistance and related cardiovascular problems, and (2) short-telomere cancers. The rest of this conversation focuses on the tests that the two clinics use to confirm MASLD or MASH and their approaches to treating multi-metabolic patients.

Listener questions? We got 'em. Voicemails? We have those, too! In this episode of MASH Matters, Jeff & Ryan knock a few more questions off the top of the overflowing mailbag. Topics range from MASH vodka dispensers and Cincinnati stalkers to the color of Hawkeye's robe and the size of Klinger's nose. We also, at long last, announce the winner of the MASH fan name poll. All this, plus... Igor is a surgeon?!? Support the podcast on Patreon and buy merch at the MASH Matters store For show notes, episodes, recipes, bios, and more visit our website.  

After far too much time away, fair-weather co-host Ash Frith rejoins CheapShow just ahead of its 450th episode and what an episode! It's a nice chunky one that throws Ash in at the deep end straight from the start. They've all got a lot to catch up on and it's been a while since they've all been in the House of Sausage and Mash. It all leads to a 40 minute diversion into the sex, drugs and Rock & Roll private lives of comedians from yesteryear! It's getting censored to F***! After that, it's time for a classic Price of Shite and, to make things more challenging for our returning guest, Eli's confidence and ego is off the charts. There is a mix of tat, toys and musical surprises that must be priced rightly and Paul is struggling to juggle his loyalties! One more episode until 450, it's exciting! See pics/videos for this episode on our website: https://www.thecheapshow.co.uk/ep-449-mumchance SEE US LIVE: Oct 18th @ The Cheerful Earful Podcast Festival 2.30pm, London https://cheerfulearful.podlifeevents.com/festival/cheapshow---live-from-cheerful-earful-podcast-festival-18th-oct-2025-tickets Watch Our 10th Birthday YouTube Live Stream! https://youtube.com/live/Z18i8M3Eqac?feature=share And if you like us, why not support us: www.patreon.com/cheapshow If you want to get involved, email us at thecheapshow@gmail.com For all other information, please visit: www.thecheapshow.co.uk Like, Review, Share, Comment... LOVE US! MERCH Official CheapShow Magazine Shop: www.cheapmag.shop Send Us Stuff: CheapShow PO BOX 1309 Harrow HA1 9QJ

Send us a text00:00:00 - Surf's Up: Season 6, Episode 11 This week, we modify our usual episode structure to focus on multi-metabolic practices and constructs. The multi-metabolic practices covered this week are run by non-hepatologists who have chosen to focus on the liver in a broader cardiometabolic context. They include two practices discussed during a two-part roundtable, one run by US gastroenterologist Dr. Karen Jerome-Zapadka and the EDOM practice in Spain, run by endocrinologists. The expert interview is with Dr. Emily Andaya, an internist who helms a cardiometabolic practice in Indiana, US, that focuses on the liver. 00:14:23 - Roundtable Part I: Groundbreaker and introductionThe core of the episodes started during the weekly groundbreakers, as guests began to describe the path that brought them from single-disease specialization to the broader multi-metabolic practice.. Immediately after the groundbreakers, participants describe their clinics today, including patient population and principles underlying their approach to treatment.00:26:15 - Roundtable Part II: Tools they useGuided by Louise, the specialists discuss the devices they use to screen and stage patients and the drugs they use to treat them. One interesting item that emerges is that EDOM relies on a 0-to-4 disease severity classification, but it does not align point-by-point with the 4-point fibrosis scale common in MASH. 00:40:28 - Roundtable Part III: Training Providers in the ClinicsLouise starts this segment by asking the EDOM team how they train practitioners in their clinic. EDOM trains practitioners in nutrition and technologists in the proper use of scanning devices. Karen comments that one big issue in re-training involves the length of visits: 15 minutes for a typical GI visit vs. 60 minutes for an initial multi-metabolic session and 30 minutes for follow-ups. Along with this, the information gathering technique are different.00:50:57 - Roundtable Part IV: Patient Health and Wrap-upLouise asks participants whether and how they have measured the impact the multi-metabolic approach has on patients' health (profound in both cases) and whether they are seeing an increase in HCC. Karen sees a difference among her long-term patients, while EDOM refers patients before their fibrosis reaches cirrhosis stage. In the last part of the episode, panelists share perspectives on how their initial specialties fit with the broader multi-metabolic practice and the kinds of impact they can have on patients.01:12:50 - Expert: Dr. Emily Andaya discusses US initiatives in multi-metabolic healthThis week's expert is Dr. Emily Andaya, an Indiana (US)-based internist whose practice has expanded to take on a multi-metabolic focus. She begins by discussing her recent attendance at the American Society for Preventive Cardiology (SPC) meeting in Boston, where she heard a talk by Dr. Christos Montzoros, an endocrinologist and multi-metabolic advocate, who emphasized the importance of incorporating the liver into preventive cardiology's focus. Louise and Emily agree that cardiometabolic focus involves evaluating general, overall health, but Emily discusses how this might require a deeper or broader testing protocol for each target organ. Emily describes the 4-point CKM scale and Louise asks how fibrosis or NAS scoring, as deployed in the MASH CRN system, might be valuable here. This is a far-ranging conversation, but one special point of interest involves the psychological benefit of telling a patient they need to treat one (multi-metabolic) condition, instead of separate heart, kidney, endocrinological and liver conditions, which might feel far more overwhelming. 01:48:48 - ConclusionBecause Roger is on vacation, there is no business report this week.

We took the classic game of MASH, threw in our favorite (and least favorite) fantasy book characters, powers, pets, and enemies… and the results were absolutely unhinged.

Send us a textThis week's expert is Tim Jobson, Medical Director of Predictive Health Intelligence, a UK-based consultancy. Tim joins Louise Campbell and Roger Green to share an update on PHI's Somerset UK project and other activities. The Somerset pilot was designed to help the NHS identify untreated patients at high risk for liver disease and bring them to the office for screening. Tim describes hepatoSIGHT, a tool that "allows clinicians to get their hands on the data and to find patients both for treatment and for clinical trials."  He describes it as standard in Somerset, UK, now, and proceeds to share new data about the patient experience. This is a unique program in that providers reach out to tell individual patients they should visit the physician based on information found in their medical records. Interestingly, patient response is overwhelmingly positive. Louise shares data indicating that 94% of individuals located by the NHS in this manner visited their GPs. Six in ten respondents rated their satisfaction with the process, giving it a mean of 4.8 on a 5-point scale. Tim also shared some preliminary modeling suggesting that sustained use of hepatoSIGHT could increase clinical trial participation as much as 50-fold if trial sites had the capacity to take all these patients. Based on the results of the pilot, hepatoSIGHT is now standard throughout the Somerset region and is being evaluated for broader use. Tim and Louise both point out that this represents a major advance in the applied use of preventive hepatology. In all, this is a warming, affirming look at whether and how patients know they benefit from what we ask them to do and share.   

Send us a textThis conversation is the first segment of SurfingMASH's July discussion of key events from the first six months of 2025. Co-hosts Jörn Schattenberg, Louise Campbell and Roger Green each chose one topic of personal interest.  Today, Jörn Schattenberg discusses two recent papers that demonstrate differences in how individual patients respond to different proteomic tests and what this can mean for individualized treatment plans. Jörn begins by citing Modulation of megabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis, a paper from researchers at Novo Nordisk that Nature magazine posted online on July 21. In this paper, the researchers utilized proteomic testing (aptamer-based SomaSignal NASH tests) to determine whether semaglutide successfully addressed different NAS score elements: steatosis, lobular inflammation, hepatocyte ballooning and fibrosis. The proteomics-based tests indicated an improvement in all four of these elements, but the elements that improved and the amounts of improvement varied among individuals. To Jörn, this suggests that we can use an individual patient's proteomic results to tailor individualized therapy based on the areas in need of improvement, so that the prescriber would know whether the best approach to resolve NAS and reduce fibrosis was one that focused on metabolic issues vs. specific anti-fibrotic effects in the liver. He supports this idea by referring to a paper he had published in JHep Reports. In this paper, he and his colleagues looked at semaglutide Phase 1 and 2 obesity trials, where MASLD was not a criterion for entry. However, analyzing individual patients with the SomaLogic panel revealed that many had some form of MASLD and that semaglutide therapy could resolve the specific MASLD issues. The rest of the conversation focused on Jörn's conclusion and the potential for tailoring treatment plans to the individual. Lousie hailed the entire concept as extremely helpful not only in selecting a pharmacotherapy but also in providing patients with information they could use to improve their health further. Roger suggests that the kinds of proteomic tests Jörn describes can lead to first-line multi-agent pharmacotherapy to address the disease with agents that collectively will address the individual patient's profile. 

Whatsup y'all! This time we coming at ya'll with a review of the album from Rome Streetz & Conductor Williams Trainspotting. Rome Streetz & Conductor Williams teamed up, knowing their past work we knew to keep this album on our radar. Hope ya'll enjoy the review.DeadLeigh's favorite tracks: Andre Agassi, Rule 4080, & Electric SlideRay's favorite tracks: M*A*S*H, Blood In His Boogers, & Connie's RevengeInstagram & Twitter: @TheHipHopBabiesFor everything THHB: https://linktr.ee/thehiphopbabies#THHB #RomeStreetz #ConductorWilliams #Trainspotting #HipHop #rap #rapper #griselda #hiphop2025 #hiphopculture #albumreview #albumreaction #music

We are diving back into the fascinating and often frustrating world of direct-to-consumer (DTC) sales. We're thrilled to reconnect with Ari Sussman and welcome Bruce Fougere, co-founder of MASH Networks, a data-driven software company that's truly shaking things up. Ari wastes no time stressing why DTC isn't just an option for distilleries anymore—it's essential. MASH Networks is arming brands with the crucial tools they need to cut through the noise and break those geographic barriers. Bruce then pulls back the curtain on how their tech leverages data and powerful storytelling to turn casual buyers into lifelong fans. We also talk about how all of this has to build on customer loyalty and why consumers are looking meaningful engagement in the brands they support. Show Notes: MASH Networks' impact on craft distilling. The importance of DTC in the evolving market. Effective use of customer data and analytics. Insights from Mammoth Distillery case study. Utilizing QR codes for consumer engagement. Building emotional connections and community. Strategies for tasting experiences and promotions. Exploring subscription models in craft spirits. Support this podcast on Patreon Learn more about your ad choices. Visit megaphone.fm/adchoices

"I was scamming them left and right." Everybody knows that when you stayed home from school you watched Price is Right and rooted for Plinko. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Episode Summary Wellness pioneer and bestselling author Doug Evans reveals how sprouting can transform your health and wallet. Learn how to grow nutrient-dense vegetables on your countertop in just 5 days for under $1 per serving. Doug shares his incredible journey from fast food addiction to thriving on living foods, and explains why sprouts are up to 100x more nutritious than mature vegetables. Guest Bio Doug Evans is a visionary entrepreneur, wellness advocate, and bestselling author of The Sprout Book. He co-founded Organic Avenue, one of the first organic cold-pressed juice brands in the US, and later created The Sprouting Company, making it easier than ever for people to grow nutrient-dense food at home. Key Topics Covered Doug's Health Transformation From eating 4 cotton candies at basketball games to a plant-based lifestyle His typical McDonald's meal: Big Mac, Quarter Pounder, 9-piece nuggets, large fries, vanilla shake, apple pie, and hot fudge sundae Lost family members to diabetes, cancer, and heart disease before discovering plant-based nutrition Started sprouting 30 years ago after seeing sprouts at Union Square Farmers Market Why Sprouts Are Nutritional Powerhouses Up to 100x more nutrient-dense than mature vegetables Sprouted lentils increase vitamin C by 300% and quadruple antioxidants in just 3 days Travel only 2 feet (counter to table) vs. 2,000 miles for average vegetables You eat the entire plant: root, shoot, endosperm, and embryo Top Sprouts & Their Benefits Broccoli sprouts: Highest in sulforaphane (anti-cancer compound), most bioavailable on day 3 Alfalfa: More beta-carotene than GMO golden rice, plus vitamin C and chlorophyll Sprouted legumes (mung beans, lentils, chickpeas): High in amino acids, keep you full Red clover: Beautiful texture, mild flavor, great crunch Getting Started with Sprouting 1/4 cup of seeds = 5 cups of sprouts in 5 days Costs under $1 per serving No soil, sunshine, or fertilizer needed The Sprouting Company's jar features: larger vessel, better drainage, stainless steel filter Seeds are tested for pathogens and microplastics How to Use Sprouts Add to any meal: salads, smoothies, juices, wraps Mash with avocado and wrap in nori for quick meal Top pizzas, tamales, soups - increases nutrition 1000x Can eat directly from the jar as a snack Store fresh homegrown sprouts for over a week Key Takeaways Sprouts are vegetables, not just garnishes - they can be entire meals Growing your own eliminates plastic packaging and ensures freshness Perfect for food deserts or anyone wanting local, organic produce year-round The most nutritious food is paradoxically also the lowest cost Sprouting breaks you free from processed foods and reconnects you with natural flavors Resources Mentioned The Sprout Book by Doug Evans Eat to Live by Dr. Joel Fuhrman The Sprouting Company: TheSproutingCompany.com Follow Doug: @dougevans on Instagram and TikTok Notable Quotes "What if I told you that you can grow the most nutrient dense food on the planet in five days on your kitchen countertop, without soil, without sunshine, without fertilizer?" "Everybody should be sprouting, everybody should be eating sprouts." "Most people are living to eat... but we should eat to live." "The world is hungry for fresh produce, and miraculously, sprouts grow in all climates, all seasons, all geographies." Host Stacey Heiney (Guest host for The NHL Today Podcast) Organic farmer and wellness advocate FREE Resource: Get Stacey's healthy vegan Sauces, Dips & Dressings e-book: https://theherbanfarmacy.mykajabi.com/the-secret-is-in-the-sauce Website: theherbanfarmacy.com Instagram: @theherbanfarmacy Connect with Doug Instagram: @dougevans TikTok: @dougevans Website: TheSproutingCompany.com Doug answers questions and supports the sprouting community directly Note: Doug lived exclusively on sprouts for 30-day periods while living in the Mojave Desert, proving their complete nutritional value.

Huntr_x - What It Sounds Like (Tristan Jaxx x Arturo Estrada, Luis Vasquez, Puffcorn Mash) by Tristan Jaxx

Gastroenterologist Anuj Vikrant Sharma discusses his article, "Fatty liver disease is no longer reserved for older adults." He warns of a quiet epidemic of metabolic dysfunction-associated steatohepatitis (MASH), a serious liver condition now increasingly appearing in people in their 20s and 30s who may not appear outwardly unhealthy. Anuj explains that a primary, and often overlooked, driver is the gut-liver axis. The modern Western diet, high in ultra-processed, low-fiber foods, disrupts the gut microbiome, leading to a "leaky gut" that allows harmful substances to travel to the liver and cause inflammation and fat accumulation. The conversation explores why this connection explains the rise of MASH in younger, non-obese patients and makes a compelling case for a "gut-first" strategy. Listeners will learn why we need earlier screening and a renewed focus on food quality over calorie counting to prevent and reverse this silent but progressive disease before irreversible damage occurs. Careers by KevinMD is your gateway to health care success. We connect you with real-time, exclusive resources like job boards, news updates, and salary insights, all tailored for health care professionals. With expertise in uniting top talent and leading employers across the nation's largest health care hiring network, we're your partner in shaping health care's future. Fulfill your health care journey at KevinMD.com/careers. VISIT SPONSOR → https://kevinmd.com/careers Discovering disability insurance? Pattern understands your concerns. Over 20,000 doctors trust us for straightforward, affordable coverage. We handle everything from quotes to paperwork. Say goodbye to insurance stress – visit Pattern today at KevinMD.com/pattern. VISIT SPONSOR → https://kevinmd.com/pattern SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast RECOMMENDED BY KEVINMD → https://www.kevinmd.com/recommended

Should the numbers on your malt COA be produced from a mash that's more similar to your brewery mashes? Did you know that's already happening when you buy UK malt? Listen up, then join the conversation (https://community.mbaa.com/communities/community-home/digestviewer/viewthread?GroupId=37&MessageKey=c1d189f2-57d6-4047-8b26-f993a3f04a11&CommunityKey=cb7fc054-5008-4b01-87f3-588d3c711e07&tab=digestviewer&ReturnUrl=%2fcommunities%2fcommunity-home%2fdigestviewer%3ftab%3ddigestviewer%26CommunityKey%3dcb7fc054-5008-4b01-87f3-588d3c711e07). Special Guests: Glen Fox and Mary-Jane Maurice.

Keren, Drex, Shannon and some guy sit down with Alisa to play the children's game MASH with her. (for her first time somehow)   Magician: Zak Mirz Sat Aug 9, 2025   Zak Mirs is a first-generation American as his parents immigrated from Iran and Afghanistan. Growing up, Zak turned to magic as an escape from reality and he found it was something he could share. Today as a professional magician, Zak tours worldwide with his stage show to share wonder and the message of hope with his audiences! https://lyricperformingartscompany.thundertix.com/events/243872 Zak Webb In Concert Sat - Aug 23, 2025 - 7:30pm CDT   Zak Webb "Notes, Chords, and Rhythm Concert" features all original music! This rare concert will showcase a variety of new and previously released songs highlighting the incredible talent of Zak Webb Music! https://lyricperformingartscompany.thundertix.com/events/250690    Concert: Jody Nix Sat - Aug 30, 2025 - 7:30pm CDT   Jody Nix, a well established artist in the great State of Texas gives Glory and Thanks to God for the talent, and the ability to use it to play music that he dearly loves. A true Traditional Country Music and Western Swing artist, he has been in the business 64 years. He has played dances and shows all over Texas and parts of the southwest. He leads one of the finest dance bands in Texas, they fill the floor on every song! https://lyricperformingartscompany.thundertix.com/events/243871    Our Presenting Sponsor for this episode is Donnie Evetts Local Real Estate Professional with The Followwell Property Group Keller Williams. Make buying or selling easy, Call Donnie Evetts. 325-998-5575!

We are back for episode 241 where we look at an entirely different type of "mind crime". We start off with 1982's "The Clairvoyant" also known as "The Killing Hour". This focuses on an artist who has violent dreams that seem to be depicting a series of murders around the city. It's a totally solid thriller with a truly surprising twist at the end. We follow that with a real rarity, a film from 1992 called "Small Kill". It features a surprising lead performance from none other than MASH's own Radar O'Reilly, Gary Burghoff as a murderous pedophile and extortionist. It's good, grim stuff with mostly solid performances and plenty of scenes that will completely skeeve you out. We recommend both movies very highly. Please let us know what you thought of the show, and send us some suggestions for future episodes. You can email us at flickersfrom@yahoo.com or flickersfrom@gmail.com. You can also reach us on Facebook, Instagram and Twitter.

Another M*A*S*H Table Read? YES! Jeff & Ryan are proud to bring you a MASH Matters EXCLUSIVE: Unedited, never-before-heard audio of another M*A*S*H table read!   The table read recording of the episode “War Co-Respondent” was recorded by David Odgen Stiers for Michael Hirsh (creator of MAKING MASH and MEMORIES OF MASH).    Written & directed by Mike Farrell, this 1980 episode was the 23rd episode of season eight and features special guest star Susan St. James.   We hope you enjoy being a fly on the wall at Stage 9... but, please, go easy on BJ, will ya? Support the podcast on Patreon and buy merch at the MASH Matters store For show notes, episodes, recipes, bios, and more visit our website.  

01.08.25 Pt 1 - Gareth Cliff kicks off Friday with Mash as they spill the beans on coffee — and why some brews are actually just chicory in disguise. They dive into the curious craze around Lebubu dolls, unpacking why these creepy collectibles are flying off shelves. Plus, a spicy debate on France's first “woman” and the controversies swirling around her gender identity. The Real Network

01.08.25 Pt 2 - Gareth Cliff and Mash get real about whether ugly people are getting enough action—and why Mash believes there truly is someone for everyone. Plus, meet Winston, the new office dog stealing hearts around the studio. And just when you think it's all smooth, terrible gym habits creep in, sparking a hilarious chat about someone who's been shaving way too much… in the toilet! The Real Network

Writer of “Jaws" & "The Jerk" Carl Gottlieb talks about working with Spielberg, Steve Martin, Carl Reiner, David Crosby, Joan Baez, improv group The Committee, performing comedy in the army, how the Smothers Brothers Show was the hippest most popular show at the time and somehow also cancelled. Bio:  Carl Gottlieb is a screenwriter (Jaws, The Jerk), director (Caveman), & actor (Mash). His book, THE JAWS LOG, remains the most popular book about the making of a motion picture ever written.  He also wrote WHICH WAY IS UP with Richard Pryor. He was a member of the classic San Francisco Improv group, The Committee.  And a writer on the controversial Smothers Brothers show. He served on the Board of Directors of the Writers Guild of America, and was on the faculty of the Film Division of the School of the Arts at Columbia University, the American Film Institute, the University of Miami's School of Communications and the University of Southern California's School of Cinema & Television.